(Q46461137)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18657224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

title

The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18657224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference

7

Roman A Blaheta

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18657224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

author name string

Jon Jones

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18657224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Eva Juengel

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18657224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Ausra Mickuckyte

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18657224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Lukasz Hudak

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18657224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Steffen Wedel

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18657224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Dietger Jonas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18657224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

publication date

24 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18657224%20AND%20SRC:MED&resulttype=core&format=json

Journal of Cellular and Molecular Medicine

11 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18657224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18657224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

page(s)

2376-2385

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18657224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

issue

8B

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18657224%20AND%20SRC:MED&resulttype=core&format=json

Adjuvant therapy for renal cell carcinoma

11 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Enhancing the anti-angiogenic action of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Valproic acid modulates NCAM polysialylation and polysialyltransferase mRNA expression in human tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Expression and prognostic significance of cyclin D3 in ovarian adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Cyclin D2 and cyclin D3 play opposite roles in mouse skin carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Cyclin D3 action in androgen receptor regulation and prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Antiproliferative action of valproate is associated with aberrant expression and nuclear translocation of cyclin D3 during the C6 glioma G1 phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Sinusoidal swinging dynamics of the telomere repair and cell growth activation functions of telomerase in rat liver cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2008.00436.X

Systemic therapy for renal cell carcinoma

21 January 2018

1 reference

12 December 2020

Interferon-alpha 2b modulation of doxorubicin sensitivity in a multidrug resistant cell line.

1 reference

12 December 2020

Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha

1 reference

12 December 2020

Cyclin D3 protein content in human renal cell carcinoma in relation to cyclin D1 and clinico-pathological parameters

1 reference

12 December 2020

Cyclin E and p27 protein content in human renal cell carcinoma: clinical outcome and associations with cyclin D

1 reference

12 December 2020

Induction of apoptosis by combined treatment with differentiation-inducing agents and interferon-alpha in human lung cancer cells.

1 reference

12 December 2020

Down-regulation of matrix-invasive potential of human liver cancer cells by type I interferon and a histone deacetylase inhibitor sodium butyrate

1 reference

12 December 2020

Biological significance of p27 and Skp2 expression in renal cell carcinoma. A systematic analysis of primary and metastatic tumour tissues using a tissue microarray technique

1 reference

12 December 2020

Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo

1 reference

12 December 2020

Loss of p27(Kip1) CDKI is a predictor of poor recurrence-free and cancer-specific survival in patients with renal cancer

1 reference

12 December 2020

Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study

1 reference

12 December 2020

Interferons modify in vitro proliferation of human bladder transitional cell carcinoma in the presence of doxorubicin and mitomycin C

1 reference

12 December 2020

Antitumor activity of sodium valproate in cultures of human neuroblastoma cells.

1 reference

12 December 2020

Simultaneous but not sequential treatment with sodium butyrate improves the antiproliferative effect of alpha- or beta-interferon on a breast cancer cell line.

1 reference

12 December 2020

10.1111/J.1582-4934.2008.00436.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18657224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18657224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference